CDH17 CAR-NK cell therapy
/ Medigen Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 27, 2023
Development of allogenic nonviral RNA-based CAR-NK therapy targeting CDH17 in relapsed/refractory gastrointestinal cancer.
(ASCO 2023)
- " Ex vivo expanded human peripheral blood NK (Magicell-NK, Medigen, Taiwan) cells were used in this study. Our findings suggest that a non-viral based CDH17 CAR-NK cell therapy could be a potential allogeneic, off-the-shelf CAR-NK therapy candidate in GI cancer and support the rationale of further investigating it in vivo and clinical trials."
IO biomarker • Gastric Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Immune Modulation • Oncology • Solid Tumor • CDH17 • LAMP1 • TNFA
1 to 1
Of
1
Go to page
1